STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Clinical Trials Dispatch
STEP 1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
STEP 1 met its primary endpoint and did not meet one of its hierarchically tested secondary endpoints, a result which appears in the paper and in almost none of the reporting. Under a pre-specified testing hierarchy a failure at that point formally precludes claims on the endpoints below it, whatever the nominal p-values show.
The endpoint hierarchy was pre-specified in the statistical analysis plan and is reproduced in the supplementary appendix. Readers relying on the abstract will not see it. The Journal reads the analysis plan before the paper for exactly this reason.
Cross-trial comparison is the commonest error in coverage of this field. Populations differ in baseline weight, diabetes status and lifestyle-intervention intensity; durations differ; estimands differ. Two programmes reporting 15% and 20% may or may not reflect a difference between the drugs, and only a head-to-head trial settles it.
"The mean is not the interesting part and it never has been," said Dr Rafał Sikorski, toxicologist, Medical University of Warsaw. "Show me the decile plot. That is where the clinical question lives."
Our clinical-trials department is reading the supplementary appendix and will publish a design note if the analysis plan differs materially from the published methods.
Note
Trial results describe populations, not individuals. Nothing in this item is clinical advice.
Related coverage
Stepping down against stopping: two decisions treated as one
The best argument for tapering is behavioural rather than pharmacological, and it deserves to be made on its own terms.
SURMOUNT-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Tapering: a word borrowed from drugs with withdrawal syndromes
These agents produce no dependence and no withdrawal syndrome. What a taper would be for is therefore a real question rather than an obvious one.
Why "muscle-sparing" is a marketing term and not a measurement
The rule that a quarter of weight lost is lean tissue has been in textbooks for decades and does not survive close reading.
SURPASS-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.